Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | QVT Financial Daniel Gold | 65,793,779 | $663,859,230 | 61.12% | |
| 2. | Viking Global Andreas Halvorsen | 46,013,752 | $464,278,758 | -4% | 1.48% |
| 3. | Rubric Capital Management David Rosen | 17,767,076 | $179,269,797 | -12% | 3.21% |
| 4. | Two Seas Capital Sina Toussi | 10,136,307 | $102,275,338 | -1% | 3.22% |
| 5. | Greenlight Capital David Einhorn | 5,441,167 | $54,901,375 | +4% | 2.78% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.45 | 100,000 | $1,145,000.00 | 1,462,223 | 2025-06-20 | Filing | |
| $11.46 | 577,007 | $6,612,500.22 | 37,284,108 | 2025-06-20 | Filing | |
| $11.45 | 565,266 | $6,472,295.70 | 37,861,115 | 2025-06-18 | Filing | |
| $11.19 | 200,800 | $2,246,952.00 | 38,426,381 | 2025-06-06 | Filing | |
| $11.34 | 547,430 | $6,207,856.20 | 38,627,181 | 2025-06-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 61,852,718 | $624,093,925 | 5.69% | |
| 2. | 51,666,511 | $521,315,092 | 0.03% | |
| 3. | 41,659,488 | $420,344,233 | 0.01% | |
| 4. | 40,767,590 | $411,344,983 | 0.01% | |
| 5. | 35,926,759 | $362,501,019 | 0.03% |
News See All
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Roivant Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday
We recently published a list of While Wall Street Naps, These 10 Stocks Run Wild. In this article, we are going to take a look at where Roivant Sciences Ltd.
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
The reiteration comes after the company appointed the current President and COO of Roivant, Dr. Eric Venker as CEO of Immunovant. Roivant Sciences Ltd.
Billionaire David Einhorn's 10 Stock Picks with Huge Upside Potential
David Einhorn is a widely renowned hedge fund manager who co-founded Greenlight Capital in 1996.
Billionaire Andreas Halvorsen's 10 Stock Picks With Huge Upside Potential
Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson's Tiger Management.
Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn
Wall Street has come down crashing on President Donald Trump’s sweeping tariffs, raising the risk of a trade war that could push the global economy into recession.
10 Best Low Priced Growth Stocks To Invest In
Low priced stocks usually fall under the small to mid-cap size category.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Billionaire Hedge Funds
